Aurobindo Pharma’s arm gets EIR for Unit-IV facility in Andhra Pradesh

12 Mar 2026 Evaluate

Aurobindo Pharma’s wholly owned subsidiary -- APL Healthcare has received an Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Unit-IV, located at Palchur village, Andhra Pradesh. The USFDA has classified the facility as ‘Voluntary Action Indicated’ (VAI).

The USFDA had conducted an inspection of the said facility from December 08 to December 17, 2025 and issued a ‘Form 483’ with 05 observations. 

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma Share Price

1291.40 43.45 (3.48%)
20-Mar-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1777.45
Dr. Reddys Lab 1298.95
Cipla 1255.85
Zydus Lifesciences 890.60
Lupin 2322.45
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×